Candriam SCA’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Candriam SCA’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,265	Closed	-$252K	–	852
2020 Q3	$252K	Hold	2,265	–	–	﹤0.01%	748
2020 Q2	$254K	Sell	2,265 -865	-28%	-$85.2K	﹤0.01%	741
2020 Q1	$292K	Hold	3,130	–	–	﹤0.01%	740
2019 Q4	$298K	Hold	3,130	–	–	﹤0.01%	758
2019 Q3	$239K	Sell	3,130 -1,065	-25%	-$88.5K	﹤0.01%	725
2019 Q2	$366K	Hold	4,195	–	–	﹤0.01%	770
2019 Q1	$380K	Hold	4,195	–	–	﹤0.01%	745
2018 Q4	$301K	Buy	4,195 +490	+13%	+$39.5K	﹤0.01%	745
2018 Q3	$355K	Buy	3,705 +775	+26%	+$75.1K	﹤0.01%	745
2018 Q2	$279K	Buy	+2,930	New	+$269K	﹤0.01%	742

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Candriam SCA's XBI Position: Q4 2020 in Review

Candriam SCA sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2020, closing a stake of 2,265 shares — an estimated $252K sold.

Candriam SCA first reported a position in XBI in Q2 2018 and held it in 10 quarters. The position peaked at $380K in Q1 2019. 654 funds tracked by Wall St. Rank hold XBI as of Q4 2020.

Candriam SCA reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2020 after selling out during the quarter.
Candriam SCA sold 2,265 State Street SPDR S&P Biotech ETF shares in Q4 2020, an estimated $252K.
Candriam SCA first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and held it in 10 quarters.
Candriam SCA's State Street SPDR S&P Biotech ETF position peaked at $380K in Q1 2019.
654 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.